TABLE 2

Physician-assessed response and treatment duration in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

Radiological tumour evaluationALK+ NSCLC patients (n=149)
CR8 (5.4)
PR70 (47.0)
SD34 (22.8)
PD19 (12.8)
Not realised18 (12.1)
ORR78 (52.3)
DCR112 (75.2)
Duration months (n=182)3.9 (0.4–23.0)

Data is presented as n (%) or median (range). CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: overall response rate; DCR: disease control rate.